Blood thinner showdown: sotagliflozin vs. FDA-Approved drugs in early trial
NCT ID NCT06933056
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-phase study at the University of Michigan will compare how well sotagliflozin limits platelet activation (a key step in blood clotting) against FDA-approved antiplatelet drugs. Researchers will measure blood samples from 20 healthy volunteers to see if sotagliflozin has similar or different effects. The goal is to gather initial data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATELET FUNCTION AND REACTIVITY TESTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.